73.60
-0.81 (-1.09%)
| Previous Close | 74.41 |
| Open | 74.41 |
| Volume | 1,755,100 |
| Avg. Volume (3M) | 1,116,550 |
| Market Cap | 5,092,075,008 |
| Price / Earnings (TTM) | 20.97 |
| Price / Earnings (Forward) | 8.89 |
| Price / Sales | 2.71 |
| Price / Book | 3.33 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 |
| Profit Margin | 16.55% |
| Operating Margin (TTM) | 27.38% |
| Diluted EPS (TTM) | 3.51 |
| Quarterly Revenue Growth (YOY) | 0.80% |
| Quarterly Earnings Growth (YOY) | -44.30% |
| Total Debt/Equity (MRQ) | 52.78% |
| Current Ratio (MRQ) | 5.74 |
| Operating Cash Flow (TTM) | 525.08 M |
| Levered Free Cash Flow (TTM) | 241.87 M |
| Return on Assets (TTM) | 14.39% |
| Return on Equity (TTM) | 24.11% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Lantheus Holdings, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.5 |
| Average | 0.88 |
|
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 2.24% |
| % Held by Institutions | 116.12% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 109.00 (B. Riley Securities, 48.10%) | Buy |
| Median | 71.50 (-2.85%) | |
| Low | 63.00 (Truist Securities, -14.40%) | Hold |
| Average | 78.75 (7.00%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 61.93 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 12 Aug 2025 | 63.00 (-14.40%) | Hold | 57.20 |
| JMP Securities | 07 Aug 2025 | 73.00 (-0.82%) | Buy | 54.86 |
| Mizuho | 07 Aug 2025 | 70.00 (-4.89%) | Buy | 54.86 |
| B. Riley Securities | 23 Jun 2025 | 109.00 (48.10%) | Buy | 80.81 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Aug 2025 | Announcement | Lantheus Announces FDA Acceptance of NDA for New Formulation for Market-Leading PSMA PET Imaging Agent |
| 23 Jul 2025 | Announcement | Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time |
| 22 Jul 2025 | Announcement | Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D |
| 11 Jun 2025 | Announcement | Lantheus Announces Presentations to be featured at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting |
| 10 Jun 2025 | Announcement | Lantheus to Present at the 2025 Truist Securities MedTech Conference |
| 03 Jun 2025 | Announcement | Lantheus to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 |
| 02 Jun 2025 | Announcement | PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |